S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
NASDAQ:BPTH

Bio-Path - BPTH Stock Forecast, Price & News

$3.93
-0.01 (-0.25%)
(As of 08/18/2022 03:59 PM ET)
Add
Compare
Today's Range
$3.92
$3.93
50-Day Range
$3.43
$4.43
52-Week Range
$2.68
$8.62
Volume
271 shs
Average Volume
26,310 shs
Market Capitalization
$28.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Bio-Path MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
128.4% Upside
$9.00 Price Target
Short Interest
Healthy
3.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Bio-Path in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($1.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

707th out of 1,119 stocks

Pharmaceutical Preparations Industry

347th out of 549 stocks

BPTH stock logo

About Bio-Path (NASDAQ:BPTH) Stock

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BPTH shares. HC Wainwright reduced their target price on Bio-Path from $12.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday, May 18th. StockNews.com assumed coverage on Bio-Path in a report on Wednesday. They issued a "sell" rating for the company.

Bio-Path Stock Performance

BPTH opened at $3.94 on Thursday. The business has a 50 day moving average price of $3.89 and a 200 day moving average price of $3.58. Bio-Path has a twelve month low of $2.68 and a twelve month high of $8.62. The firm has a market cap of $28.21 million, a P/E ratio of -2.23 and a beta of 1.48.

Bio-Path (NASDAQ:BPTH - Get Rating) last posted its earnings results on Tuesday, August 16th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.08. During the same period last year, the business earned ($0.26) earnings per share. As a group, analysts anticipate that Bio-Path will post -1.89 earnings per share for the current fiscal year.

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Stock News Headlines

Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com
StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)
See More Headlines
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Company Calendar

Last Earnings
8/16/2022
Today
8/18/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+129.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.56 per share

Miscellaneous

Free Float
6,997,000
Market Cap
$28.14 million
Optionable
Not Optionable
Beta
1.48

Key Executives

  • Mr. Peter H. Nielsen MBA (Age 73)
    Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
    Comp: $680.18k
  • Mr. Douglas P. Morris (Age 66)
    Co-Founder, Director of Investor Relations, Sec. & Director
    Comp: $68.47k
  • Mr. Anthony Price
    Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D.
    MBA, Sr. VP of Research, Devel. & Clinical Design
  • Dr. Alan MacKenzie Ph.D.
    Consultant
  • Dr. Thomas A. Walker Ph.D.
    Consultant
  • Dr. Jeffery Lancet M.D.
    Consultant
  • Ms. Victoria Lake Rac
    Regulatory Consultant













BPTH Stock - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings
or view top-rated stocks.

What is Bio-Path's stock price forecast for 2022?

1 equities research analysts have issued twelve-month price objectives for Bio-Path's shares. Their BPTH share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 128.4% from the stock's current price.
View analysts price targets for BPTH
or view top-rated stocks among Wall Street analysts.

How have BPTH shares performed in 2022?

Bio-Path's stock was trading at $3.77 at the beginning of the year. Since then, BPTH stock has increased by 4.5% and is now trading at $3.94.
View the best growth stocks for 2022 here
.

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BPTH earnings forecast
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) issued its quarterly earnings data on Tuesday, August, 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.08. During the same period in the prior year, the firm posted ($0.26) EPS.

When did Bio-Path's stock split?

Shares of Bio-Path reverse split on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.25%).
View institutional ownership trends
.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $3.94.

How much money does Bio-Path make?

Bio-Path (NASDAQ:BPTH) has a market capitalization of $28.21 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for the company is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com.

This page (NASDAQ:BPTH) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.